Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?

BACKGROUND: The TRITON-TIMI 38 study has identified three subgroups of patients with a higher risk of bleeding during treatment with the thienopyridine prasugrel: patients with a history of stroke or transient ischaemic attack (TIA), patients ≥75 years and patients with a body weight <60 kg. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Breet, N. J., van Donkersgoed, H. E., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Zijlstra, F., Hackeng, C. M., ten Berg, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111569/
https://www.ncbi.nlm.nih.gov/pubmed/21494888
http://dx.doi.org/10.1007/s12471-011-0105-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111569/
https://www.ncbi.nlm.nih.gov/pubmed/21494888
http://dx.doi.org/10.1007/s12471-011-0105-5

Ejemplares similares